Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 19/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1004737 | 1.00 | MCHR1 (0.63) | MCHR1KCNH2HRH3 | |
| SCHEMBL2894221 | 0.91 | MCHR1 (0.76) | MCHR1KCNH2HRH3 | |
| SCHEMBL2882906 | 0.89 | MCHR1 (0.59) | MCHR1KCNH2HRH3 | |
| SCHEMBL1003118 | 0.89 | MCHR1 (0.59) | MCHR1KCNH2HRH3 | |
| SCHEMBL1003063 | 0.89 | MCHR1 (0.59) | MCHR1KCNH2HRH3 | |
| SCHEMBL1000731 | 0.86 | MCHR1 (0.82) | MCHR1KCNH2HRH3 | |
| SCHEMBL1002408 | 0.82 | MCHR1 (0.57) | MCHR1KCNH2 | |
| SCHEMBL1003609 | 0.82 | MCHR1 (0.57) | MCHR1KCNH2 | |
| SCHEMBL2880703 | 0.82 | MCHR1 (0.57) | MCHR1KCNH2 | |
| SCHEMBL2887086 | 0.82 | MCHR1 (0.75) | MCHR1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875633-B2 | 4-[(4-Chlorobenzyl)oxy]-1-(4-[(1E)-3-(methylamino)-1-propen-1-yl]phenyl)pyridin-2(1H)-one; remedy for metabolic disorders such as obesity, diabetes, hormone disorder; cardiovascular disorders (stenocardia, acute or congestive heart failure); nervous system disorders (bulimia, anxiety, epilepsy etc.) | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| EP-1921065-B1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20090137587-A1 | Phenylpyridone Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1921065-A1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137587-A1 | Phenylpyridone Derivative | NAT1, NPR1, PC | MCHR1 439/4885KCNH2 781/4885HRH3 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.